Ferroportin inhibitors

US10738041B2 · kind B2 · utility

Assignee

• Vifor (International) AG · CH

Inventors

• Franz Dürrenberger · Dornach, CH
• Wilm Buhr · Konstanz, DE
• Susanna Burckhardt · Zürich, CH
• Michael Burgert · Friedrichshafen, DE
• Aris Kalogerakis · Winterthur, CH
• Stefan Reim · Sankt Gallen, CH
• Vania Manolova · Zollikon, CH
• Susan Boyce · Quickborn, DE
• Christopher John Yarnold · Shrewsbury, GB
• Paula Pena · Witney, GB
• Jon Shepherd · Abingdon, GB
• Cristina Lecci · Abingdon, GB
• Richard Jarjes-Pike · Newbury, GB
• John Scott · Abingdon, GB

Key dates

• Filing date: Oct 21, 2016
• Grant date: Aug 11, 2020
• Expiry date: Oct 21, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.